Development of a Novel Method for Determination of 11 Antiretroviral Drugs Concentrations in Human Plasma by Ultra-Performance Liquid Chromatography- Photodiode Array Detection Method
Keywords:
UPLC/PDA; antiretroviral; therapeutic drug monitoringAbstract
Objective: To develop ultra-performance liquid chromatography-photodiode array detection (UPLC-PDA) method that is fully validated for measuring 11 antiretroviral drugs concentrations in human plasma.
Methods: Chromatographic separation was performed on an ACQUITY UPLC™ BEH Shield RP, 1.7 μm (100 mm x 2.1 mm I.D.) and used acetronitrile with 0.1% formic acid in Milli-Q water as a mobile phase. ACQUITY UPLC®
Photodiode Array (PDA) Detector was performed at 210, 240, and 260 nm.
Results: This method demonstrated a good separation result for plasma levels of 11 antiretroviral drugs within 16 minutes. The lower limit of quantification (LLOQ) was 0.25 μg/mL for maraviroc, 0.5 μg/mL for lopinavir, and
20 ng/mL for the remaining 9 antiretroviral drugs. This method was fully validated in terms of selectivity, accuracy, precision, and stability. The standard curves are in the expected ranges of drug concentration in the patients’ plasma with good linearity (r2>0.995). Recoveries of extraction ranged from 72.27- 110.80% with repeatability.
Conclusion: A novel, sensitive, accurate, and reproducible UPLC/PDA method for quantification of 11 currentlyprescribed antiretroviral drugs concentrations in human plasma was successfully developed and fully validated according to USFDA guidelines.
Downloads
Published
How to Cite
Issue
Section
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.